Metabolic modeling-based drug repurposing in Glioblastoma
Claudio Tomi-Andrino
(Centre for Analytical Bioscience, Advanced Materials and Healthcare Technologies Division, School of Pharmacy, University of Nottingham)
Alina Pandele
(Children’s Brain Tumour Research Centre, Biodiscovery Institute, School of Medicine, University of Nottingham)
Klaus Winzer
(Nottingham BBSRC/EPSRC Synthetic Biology Research Centre (SBRC), School of Life Sciences, BioDiscovery Institute, University of Nottingham)
John King
(Nottingham BBSRC/EPSRC Synthetic Biology Research Centre (SBRC), School of Mathematical Sciences, University of Nottingham)
Ruman Rahman
(Children’s Brain Tumour Research Centre, Biodiscovery Institute, School of Medicine, University of Nottingham)
Dong-Hyun Kim
(Centre for Analytical Bioscience, Advanced Materials and Healthcare Technologies Division, School of Pharmacy, University of Nottingham)
Abstract The manifestation of intra- and inter-tumor heterogeneity hinders the development of ubiquitous cancer treatments, thus requiring a tailored therapy for each cancer type. Specifically, the reprogramming of cellular metabolism has been identified as a source of potential drug targets. Drug discovery is a long and resource-demanding process aiming at identifying and testing compounds early in the drug development pipeline. While drug repurposing efforts (i.e., inspecting readily available approved drugs) can be supported by a mechanistic rationale, strategies to further reduce and prioritize the list of potential candidates are still needed to facilitate feasible studies. Although a variety of ‘omics’ data are widely gathered, a standard integration method with modeling approaches is lacking. For instance, flux balance analysis is a metabolic modeling technique that mainly relies on the stoichiometry of the metabolic network. However, exploring the network’s topology typically neglects biologically relevant information. Here we introduce Transcriptomics-Informed Stoichiometric Modelling And Network analysis (TISMAN) in a recombinant innovation manner, allowing identification and validation of genes as targets for drug repurposing using glioblastoma as an exemplar.
Claudio Tomi-Andrino, Alina Pandele, Klaus Winzer, et al. (2022). "Metabolic modeling-based drug repurposing in Glioblastoma". Scientific Reports. https://doi.org/10.1038/s41598-022-14721-w